Produits Chimiques Auxiliaires et de Synthèse SA

Produits Chimiques Auxiliaires et de Synthèse SA

Produits Chimiques Auxiliaires et de Synthèse SA

Overview
Date Founded

1962

Headquarters

23, rue Bossuet,Z. I. de la Vigne aux Loups,Longjumeau, Ile-de-France 91160

Type of Company

Public

Employees (Worldwide)

1,071

Industries

Chemicals

Company Description

Produits Chimiques Auxiliaires et de Synthèse SA engages in developing, manufacturing and selling of chemicals. It operates through the Pharmaceutical Synthesis and Fine Chemical sectors. The Pharmaceutical Synthesis sector manufactures active ingredients, generics, and biomaterials. The Fine Chemical sector comprises of polymers and insulators. The company was founded in 1962 and is headquartered in Longjumeau, France.

Website
Executives & Employees

Chief Executive Officer

Vice Chief Executive Officer

Chief Operating Officer

Deputy Chief Executive Officer-Finance & Administration

Scientific Director

Director-Research & Development

Financial Communication

Board of Directors

General Manager at L'Agence Nationale de la Recherche

Former Chief Executive Officer at Quantel SA

Chief Executive Officer at Novacap SASU

Former Auditor at PricewaterhouseCoopers Afrique

Group Chief Financial Officer at Novacap SASU

General Counsel at Novacap SASU

Member, Board of Directors at Produits Chimiques Auxiliaires et de Synthèse SA

Paths to Produits Chimiques Auxiliaires et de Synthèse SA
Potential Connections via
Relationship Science
You
Produits Chimiques Auxiliaires et de Synthèse SA
Owners & Shareholders
Details Hidden

Portzamparc Gestion manages mutual funds as well as discretionary portfolios. Their investment process is primarily based on fundamental research, both in-house and shared within the parent group, which is complemented with the quantitative expertise of B*Capital. Their investment approach consists in security picking across asset classes, within the constraints of their clients' risk tolerance profile. They provide to their clients access to third-party products through an open architecture.In terms of equity Portzamparc Gestion invests both directly and through equity funds. Their direct investments favor French and European mid-caps. They have specific expertise in regional small and mid caps.

Details Hidden

Portzamparc Gestion manages mutual funds as well as discretionary portfolios. Their investment process is primarily based on fundamental research, both in-house and shared within the parent group, which is complemented with the quantitative expertise of B*Capital. Their investment approach consists in security picking across asset classes, within the constraints of their clients' risk tolerance profile. They provide to their clients access to third-party products through an open architecture.In terms of equity Portzamparc Gestion invests both directly and through equity funds. Their direct investments favor French and European mid-caps. They have specific expertise in regional small and mid caps.

Recent Transactions
Details Hidden

Eurazeo Capital, Novacap International SAS purchase Produits Chimiques Auxiliaires et de Synthèse SA

Details Hidden

Eurazeo Capital, Novacap International SAS purchase Produits Chimiques Auxiliaires et de Synthèse SA

Details Hidden

MML Capital Partners LLP, Nactis SAS purchase Produits Chimiques Auxiliaires et de Synthèse SA /AromaticBus from Produits Chimiques Auxiliaires et de Synthèse SA

Transaction Advisors
Legal Advisor

Advised onEurazeo Capital, Novacap International SAS purchase Produits Chimiques Auxiliaires et de Synthèse SA

Investment Advisor

Advised onEurazeo Capital, Novacap International SAS purchase Produits Chimiques Auxiliaires et de Synthèse SA

Clients

Corcept Therapeutics, Inc. engages in the development of drugs for the treatment of severe psychiatric, neurological, and metabolic disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

Merck KGaA engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, and Performance Materials. The Healthcare sector discovers, develops, and manufactures prescription medicines used to treat cancer, multiple sclerosis, and infertility. The Life Science sector provides scientists with laboratory materials, technologies, and services. The Performance Materials sector develops specialty chemicals and materials for demanding applications. The company was founded by Friedrich Jacob Merck in 1668 and is headquartered in Darmstadt, Germany.

Bukwang Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products. Its products include gastrointestinal, central nervous system and metabolic drugs. The company also sells household supplies and gift sets. Bukwang Pharmaceutical was founded on October 17, 1960 and is headquartered in Seoul, South Korea.

Key Stats and Financials As of 2017
Market Capitalization
$250M
Total Enterprise Value
$315M
Earnings Per Share
$0.44
Revenue
$218M
Net Profit
$6.15M
EBITDAMargin
11.88%
Enterprise Value Sales
1.44x
Total Equity
$104M
EBITDA
$25.9M
Total Debt
$64.9M
Enterprise Value EBITDAOperating
12.13x
TEVNet Income
51.12x
Debt TEV
0.21x
Three Year Compounded Annual Growth Rate Of Revenue
9.48%
Five Year Compounded Annual Growth Rate Of Revenue
4.99%